At a glance
ClinicalIndex Comparison RecordN/ACompleted· 27 enrolled
Drug / intervention
Acetyl-L-carnitinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Dose-Escalation Pilot Study of Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Dec 4, 2002·Updated Nov 1, 2021
In Brief
A clinical study evaluating Acetyl-L-carnitine for HIV Infections and Peripheral Nervous System Diseases. Completed, enrolled 27 participants across 11 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine if acetyl-L-carnitine (ALC) reduces pain, numbness, and tingling in the feet and legs of patients with nucleoside reverse transcriptase inhibitor (NRTI)-associated peripheral neuropathy. Another purpose is to determine if ALC is safe and tolerable in HIV patients who have taken certain anti-HIV drugs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Peripheral Nervous System Diseases
CountriesPuerto Rico, United States
CollaboratorsNeurologic AIDS Research Consortium (NARC)
Timeline
N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2002
Study CompletionJan 2007
TodayJul 2026
First PostedDec 4, 2002
Study CompletionJan 1, 2007
TodayJul 2, 2026
Posted 23.6 years ago
Interventions
Acetyl-L-carnitinedrug